Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alpha Tau Medical Ltd. is conducting a pivotal clinical study titled ‘A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma.’ The study aims to evaluate the efficacy and safety of Alpha DaRT224 in treating patients with recurrent cutaneous squamous cell carcinoma, focusing on objective response rate and duration of response.
The intervention being tested is the DaRT seeds, a type of device designed for intratumoral administration. This treatment involves inserting DaRT seeds into tumors, which are then reassessed and removed after a few weeks to measure the treatment’s effectiveness.
This interventional study follows a single-group model without masking, aimed at treatment. It is an open-label trial, meaning both researchers and participants know the treatment being administered.
The study began on April 1, 2022, and the latest update was submitted on September 3, 2025. These dates are crucial as they indicate the study’s progress and the timeline for obtaining results.
The update on this study could influence Alpha Tau Medical Ltd.’s stock performance by potentially boosting investor confidence if the results are positive. The study’s progress is also relevant in the context of the competitive landscape of cancer treatment technologies.
The study is ongoing, and further details are available on the ClinicalTrials portal.